论文部分内容阅读
目的 观察联合应用利塞膦酸钠和前列腺素 E2 ( PGE2 )对去卵巢大鼠骨骼的影响。 方法 利塞膦酸钠 5μg·kg- 1皮下注射 ,1周 2次 ;PGE2 6mg· kg- 1·d- 1皮下注射 ;联合用药为利塞膦酸钠 60 d停药 ,改用 PGE2 2 1和 90 d。分别于实验 60、81和 1 50 d处死大鼠 ,取胫骨上段不脱钙骨制片测量。 结果 与去卵巢模型组比较 :( 1 )利塞膦酸钠降低去卵巢所引起的骨高转化率 ,骨量在 60、81和 1 50 d均增加 ,骨小梁面积百分率分别为 ( 3 2± 4 ) %、( 3 3± 7) %和 ( 2 0± 3 ) % ;单纯用 PGE2 骨量增加 ,在 2 1和 90 d分别为 ( 2 1± 6) %和 ( 1 9± 2 ) %。 ( 2 )联合用药组 2 1和 90 d骨小梁面积明显增加 ,分别为 ( 48± 5) %和 ( 49± 7) % ,联合用药组骨转化率介于用利塞膦酸钠的去卵巢组和单用 PGE2 组之间。 结论 利塞膦酸钠能稳定去卵巢大鼠的骨骼 ,甚至可轻微的增加其骨量 ;被利塞膦酸钠抑制的骨仍能很好地与合成代谢药 PGE2 反应 ,使骨量显著增加。
Objective To observe the effects of combined use of risedronate and prostaglandin E2 (PGE2) on the bone of ovariectomized rats. Methods Rising sodium subcutaneous injection of 5μg · kg-1, twice a week; PGE2 6mg · kg-1 · d-1 subcutaneous injection; combination therapy for risedronate 60d withdrawal, use PGE2 2 1 And 90 d. The rats were sacrificed at 60, 81 and 150 days respectively, and the non-decalcified bone fragments of the upper tibia were measured. Results Compared with the ovariectomized model group, (1) risedronate decreased the rate of osteal conversion induced by ovariectomy. The bone mass increased at 60, 81 and 1 50 days, and the trabecular area percentages were (3 2 (21 ± 6)%, (19 ± 2)% and (20 ± 3)%, respectively. The bone mass of PGE2 was increased at 21 and 90 days respectively, %. (2) The trabecular area of the combination group increased significantly (48 ± 5)% and (49 ± 7)% at 21 and 90 days respectively. The bone turnover rate of the combination group was lower than that of the control group Between the ovary group and the PGE2 group alone. Conclusions Risedronate stabilizes bone in ovariectomized rats and may even slightly increase its bone mass. Bone inhibited by risedronate still responds well to the anabolic agent PGE2, resulting in a significant increase in bone mass .